Background: Open access endoscopy allows reference of patients for endoscopic procedures without prior gastrointestinal consultation, allowing the procedure to be more accessible. This practice is becoming increasingly widespread in the United States and other countries and has become commonplace in clinical practice in Israel. The objective of our study is to bring forward our experience with an open access referral system for colonoscopy and to measure the yield and safety of colonoscopy in this system.
Methods: Between January 2001 and September 2003, 10,866 colonoscopies were performed. Patient's charts were reviewed for the following data: demographics, indication for endoscopy, endoscopic and histopathologic findings, and complications. The practice guidelines of the American Society for Gastrointestinal Endoscopy were used to assess appropriateness of colonoscopy.
Results: 3533 pathologic findings were found, in 2978 colonoscopies. 2336 polyps were removed, including 18% hyperplastic, 26% tubular adenomata, 13% villous adenomata, 11% tubulovillous adenomata. Advanced disease was found in 41% of pathologic findings, 11% were invasive cancer. Rate of colonoscopies "generally indicated" according to American Society for Gastrointestinal Endoscopy guidelines was 78% with a rate of colonoscopies "generally not indicated" of 22%. Colonoscopy was completed successfully to the cecum in 93% of patients. 0.08% had serious complications during or immediately after colonoscopy.
Conclusions: Our results suggest that open access colonoscopy is a reliable and safe method for screening average risk population. As colonoscopy is becoming the recommended screening model for colorectal cancer this attitude of performing screening in an open access system could both cut costs in the future and improve availability, in an aim to become common practice.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/01.mcg.0000225573.27643.3d | DOI Listing |
IUCrJ
January 2025
Department of Physics, University of Siegen, Siegen, Germany.
The topic of data storage, traceability, and data use and reuse in the years following experiments is becoming an important topic in Europe and across the world. Many scientific communities are striving to create open data by the FAIR principles. This is a requirement from the European Commission for EU-funded projects and experiments at EU-funded research infrastructures (RIs) and from many national funding agencies.
View Article and Find Full Text PDFEur J Breast Health
January 2025
Department of Psychology, Faculty of Humanities and Social Science, Bursa Technical University, Bursa, Turkey.
A significant number of scientific data concerning breast cancer is generated in Turkey. The present research reviewed postgraduate theses examining the psychological evaluation of breast cancer patients conducted in Turkey. The objective of the review study was to ascertain the focal topics of the theses, identify commonly examined psychological variables, determine research gaps, compare the frequency of experimental and intervention studies with other kinds of research, and provide recommendations for literature.
View Article and Find Full Text PDFCureus
December 2024
Gastroenterology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GBR.
Background The aim of this study was to compare the clinical characteristics and clinical outcomes of patients who presented with acute upper gastrointestinal bleeding (AUGIB) among two groups of patients who were transferred from local and district hospitals for endoscopy and subsequent management versus direct admissions to the emergency department with AUGIB to the Sheffield University Hospital NHS Trust. Methods We included 259 patients who underwent upper GI endoscopy from April 2018 to March 2022, of whom 29 were transferred and 230 were direct admissions. The analysis focused on demographics, pathological findings, time to endoscopy, blood transfusions, and hospital stay.
View Article and Find Full Text PDFCureus
December 2024
Department of Hematology, Japanese Red Cross Medical Center, Tokyo, JPN.
Elranatamab is an effective drug for triple-class-exposed relapsed/refractory multiple myeloma (TCE-RRMM). In the pivotal study, only grade 1 or 2 immune effector cell-associated neurotoxicity syndrome (ICANS) were reported, and the risk factors for immune effector cell-associated neurotoxicity syndrome have not yet been clearly elucidated. This case report documents the first case of grade 4 ICANS in a patient treated with elranatamab, presenting alongside grade 1 cytokine release syndrome (CRS).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!